Mostafa Jarahian

List of Publications by Year in Descending Order

29 papers	1,175 citations	13 h-index	31 g-index
31 ext. papers	1,846 ext. citations	7.8 avg, IF	4.17 L-index

#	Paper	IF	Citations
29	Cloning and Embryo Splitting in Mammalians: Brief History, Methods, and Achievements. *Stem Cells International*, **2021**, 2021, 2347506	5	4
28	Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape. *Cancers*, **2021**, 13,	6.6	2
27	Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. *Stem Cell Research and Therapy*, **2021**, 12, 200	8.3	9
26	Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. *Stem Cell Research and Therapy*, **2021**, 12, 217	8.3	7
25	Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities. *Stem Cell Research and Therapy*, **2021**, 12, 297	8.3	23
24	The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses. *IUBMB Life*, **2021**, 73, 1005-1015	4.7	3
23	CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. *Frontiers in Oncology*, **2021**, 11, 673276	5.3	18
22	Up-regulation of KISS1 as a novel target of Let-7i in melanoma serves as a potential suppressor of migration and proliferation in vitro. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 6864-6873	5.6	2
21	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. *Frontiers in Immunology*, **2021**, 12, 681984	8.4	4
20	CAR T cells in solid tumors: challenges and opportunities. *Stem Cell Research and Therapy*, **2021**, 12, 81	8.3	72
19	Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. *Stem Cell Research and Therapy*, **2021**, 12, 192	8.3	35
18	CAR-NK cell in cancer immunotherapy; A promising frontier. *Cancer Science*, **2021**, 112, 3427-3436	6.9	17
17	Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy. *International Immunopharmacology*, **2021**, 96, 107762	5.8	0
16	Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 686453	5.7	3
15	A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine. *Journal of Translational Medicine*, **2021**, 19, 302	8.5	24
14	Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. *Stem Cell Research and Therapy*, **2021**, 12, 465	8.3	12
13	Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy. *Frontiers in Medicine*, **2021**, 8, 721174	4.9	4

12	Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges. *Frontiers in Immunology*, **2021**, 12, 699746	8.4	6
11	Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. *Journal of Innate Immunity*, **2021**, 1-13	6.9	1
10	Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol. *Frontiers in Bioengineering and Biotechnology*, **2021**, 9, 705886	5.8	35
9	The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. *Cancer Letters*, **2020**, 474, 82-93	9.9	12
8	Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in for Cancer Immunotherapy. *Reports of Biochemistry and Molecular Biology*, **2020**, 9, 50-57	1.3	0
7	Brain tumour cells interconnect to a functional and resistant network. *Nature*, **2015**, 528, 93-8	50.4	496
6	Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib. *Lung Cancer*, **2014**, 86, 151-7	5.9	10
5	Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. *PLoS Pathogens*, **2011**, 7, e1002195	7.6	77
4	Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. *Journal of Virology*, **2009**, 83, 8108-21	6.6	129
3	Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. *Glycobiology*, **2008**, 18, 28-41	5.8	51
2	Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. *International Journal of Cancer*, **2007**, 120, 2625-34	7.5	39
1	Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. *PLoS ONE*, **2007**, 2, e1339	3.7	79